NEURACAP
Sector OutlookPublished · 21 pages · Free to read

Neurology and CNS Therapeutics Sector Outlook — September 2026

This sector outlook examines how public markets and precedent transactions value Neurology and CNS Therapeutics companies, distinguishing clinical-stage, specialty and diversified franchise business models for investors and corporate development teams.

For information only. Not an appraisal or a fairness opinion.

What moved since: Neurology and CNS Therapeutics M&A update, 14–28 September 2026

Key figures

Sector Median EV/Revenue
3.5x
CY2027E, 14 of 26 rated companies
Premium-Tier Multiple
25.6x
EV/Revenue (CY2027E)
Discount-Tier Multiple
1.5x
EV/Revenue (CY2027E)
Margin-Led Valuation Split
3.2x
vs 1.9x below 31% EBITDA margin line

Read the report

NeuraCap

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › NEUROLOGY AND CNS THERAPEUTICS

Neurology and CNS: Value Splits by Business Model

This report shows where public valuations and precedent transactions distinguish clinical assets, marketed brands and diversified franchises.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E)

Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice

1

1 / 21

Executive summary

Neurology and CNS Therapeutics prices in tiers set by pipeline optionality and commercial durability, not by sector label. The premium end trades at 25.6x EV/Revenue (CY2027E) versus 1.5x at the discount end, and growth forecasts alone do not explain that gap. Margin is the sharper divider: names above the 31% EBITDA margin line carry 3.2x against 1.9x below it. Precedent deals, from $795M to $13.8B, show buyers paying for both marketed franchises and clinical-stage strategic fit.

Key findings

  • Valuation splits into tiers — tier membership matters more than sector label.
  • Clinical-stage biotech drives sector breadth; commercial models drive revenue.
  • Pipeline optionality separates premium and discount ends more than growth alone.
  • Precedent deals reward both marketed franchises and clinical-stage strategic fit.

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › NEUROLOGY AND CNS THERAPEUTICS

    This is the cover page introducing the Neurology and CNS Therapeutics sector outlook as of September 2026.

    We're opening our Neurology and CNS Therapeutics sector outlook, built on market data as of September 28, 2026. This deck shows why tier membership — not the sector label — is what will drive your next conversation with the market.

    Everything on this page

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › NEUROLOGY AND CNS THERAPEUTICS Neurology and CNS: Value Splits by Business Model This report shows where public valuations and precedent transactions distinguish clinical assets, marketed brands and diversified franchises. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E) Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    This slide lists the five sections and appendix that make up the report.

    We've structured this report so the bottom line comes first — read section one and you have the whole story. From there, we walk through the market landscape, valuation drivers and situations, precedent deals, and the strategic implications. So what: you can go as deep as you need, but you're never without the answer.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line Clinical Assets Command the Range, While Commercial Fit Anchors Transactions 02 The Landscape Clinical-Stage Biotech Dominates the Field, but Commercial Models Price Differently 03 Valuation & Situations The Premium End Reflects Pipeline Optionality Beyond the Forecast 04 Precedent Transactions Buyers Agreed to Pay for Marketed Brands and Strategic CNS Assets 05 Strategic Implications Strengthen the Evidence Behind Growth Before Expanding the Cost Base 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Neurology and CNS Therapeutics Is Priced in Tiers — and Tier Membership, Not the Sector Label, Sets the Conversation

    This slide summarizes the deck's core finding: valuation splits into tiers based on business model and evidence, not on sector label.

    We find that Neurology and CNS Therapeutics prices in tiers, not as one uniform sector. Clinical-stage biotech accounts for 23 of 26 companies, yet only 11 of those carry a CY2027E revenue estimate, so pipeline readouts and cash runway remain central to value. The premium end trades at 25.6x EV/Revenue against 1.5x at the discount end, and forecast growth alone does not explain that gap — margin and franchise fit do. So what: the conversation you have next depends on which tier a company sits in, not on the sector it's labeled.

    Everything on this page

    01 · THE BOTTOM LINE Neurology and CNS Therapeutics Is Priced in Tiers — and Tier Membership, Not the Sector Label, Sets the Conversation The full story on one page · figures on EV / Revenue (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (14 of 26 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (14 of 26 companies), so this report follows it. Qualitative characterisations are NeuraCap views. Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 Clinical-Stage Biotech Defines the Sector’s Breadth Clinical-stage CNS biotech accounts for 23 of 26 companies. Only 11 of those companies carry a CY2027E revenue estimate, leaving pivotal readouts, probability of technical and regulatory success and cash runway central to value. 2 The Premium End Carries Far More Pipeline Expectation The premium end sits at 25.6x versus 1.5x at the discount end on CY2027E revenue. With only 7 of 26 names carrying meaningful EBITDA, revenue is the cleaner lens for comparing launch trajectories and pipeline optionality. 3 Forecast Growth Alone Does Not Separate Value Among ten companies with growth estimates, the five above the growth bar sit at 3.0x while the five below it sit at 3.4x. Payer access, label breadth, persistence and pipeline durability remain important parts of the valuation discussion. 4 Strategic Fit Supports Transactions Across Development Stages The selected precedent transactions range from $795M for Sage Therapeutics, Inc. to $13.8B for Karuna Therapeutics, Inc. The buyer mix points to demand for both marketed CNS franchises and assets that can replenish neuroscience portfolios. 3.5x Sector median EV/Revenue CY2027E consensus · EV/Revenue is the lens because practitioners price this growth set on revenue 25.6x Premium end EV/Revenue vs 1.5x at the discount end top quartile (n=4) against bottom quartile (n=4) on EV/Revenue — the spread the report explains 11 Transactions with disclosed terms 32 recorded in this tier · 3 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    This divider introduces section two, covering the market landscape across business models.

    We're moving into the market map. Clinical-stage biotech dominates by count, but commercial models carry the revenue base — that's the split we'll unpack next.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE Clinical-Stage Biotech Dominates the Field, but Commercial Models Price Differently The sector spans clinical-stage CNS biotech, specialty neurology and diversified neuroscience franchises. 02 of 06 Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    Clinical-Stage Biotech Supplies the Breadth; Commercial Models Supply the Revenue Base

    This slide groups all 26 approved companies by business segment and shows median EV/Revenue (CY2027E) per group.

    We've grouped the universe of 26 companies by business segment — clinical-stage biotech, specialty neurology and diversified neuroscience franchises. Clinical-stage names supply the sector's breadth, while commercial models anchor the revenue base investors can underwrite today. So what: where a company sits on this map tells you what kind of evidence — clinical or commercial — will move its valuation next.

    Everything on this page

    02 · MARKET MAP Clinical-Stage Biotech Supplies the Breadth; Commercial Models Supply the Revenue Base 26 approved companies grouped by business segment · median EV / Revenue (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 CLINICAL-STAGE CNS BIOTECH 23 cos median 5.0x Jazz (JAZZ) Neurocrine (NBIX) Axsome (AXSM) Praxis Precision (PRAX) Amylyx (AMLX) ACADIA (ACAD) Xenon (XENE) Biohaven (BHVN) Stoke Therapeutics (STOK) GH Research (GHRS) Rapport (RAPP) COMPASS Pathways (CMPS) Alto Neuroscience (ANRO) Bright Minds (DRUG) +9 more This group carries the sector’s readout exposure, pipeline optionality and widest range of implied outcomes. SPECIALTY AND BRANDED-GENERIC NEUROLOGY 2 cos median 1.5x Supernus (SUPN) Collegium (COLL) Marketed brands bring visible scripts, payer dynamics and reusable specialist commercial infrastructure. DIVERSIFIED NEUROSCIENCE FRANCHISES 1 cos 3.4x · 1 rated Biogen (BIIB) Portfolio breadth reduces reliance on a single asset and creates more routes for label expansion and capital allocation.

  6. 06
    02 · LANDSCAPE

    Three Business Models Put Different Evidence Behind the Revenue Line

    This slide describes what each of the three business models does and why the distinction matters for valuation.

    We look at the three business models in the CNS universe — clinical-stage biotech, specialty neurology and diversified franchises — and how each puts different evidence behind its revenue line. Clinical-stage names are valued on pipeline probability; specialty and diversified names are valued on the durability of what they've already commercialised. So what: matching the right evidence type to each model keeps the conversation grounded in what's actually driving the multiple.

    Everything on this page

    02 · LANDSCAPE Three Business Models Put Different Evidence Behind the Revenue Line Segment view of the approved universe · EV / Revenue (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/Revenue Names to know What they do — and why it matters Clinical-stage CNS biotech 23 88% 5.0x Jazz Pharmaceuticals plc (JAZZ) · Neurocrine Biosciences, Inc. (NBIX) · +21 more Readouts carry the value. Lead-program evidence, probability of technical and regulatory success and cash runway shape how investors assess these companies before revenue matures. Specialty and branded-generic neurology 2 8% 1.5x Supernus Pharmaceuticals, Inc. (SUPN) · Collegium Pharmaceutical, Inc. (COLL) Execution carries the value. Script trends, payer coverage, persistence and loss-of-exclusivity timing shape the durability of marketed-brand revenue. Diversified neuroscience franchises 1 4% 3.4x n=1 Biogen Inc. (BIIB) Portfolio breadth carries the value. Multiple products and indications spread clinical and commercial exposure while supporting selective reinvestment across the franchise.

  7. 07
    SECTION 03

    03

    This divider introduces section three, covering public market valuation and situation analysis.

    We now turn to valuation. Even after crediting expected growth, the premium end of this sector still trades well above the discount end — pipeline optionality is doing the rest of the work.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS The Premium End Reflects Pipeline Optionality Beyond the Forecast Forward revenue valuations separate sharply even after anticipated growth is credited. 03 of 06 Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    Pipeline Optionality Separates the Premium End from the Discount End

    This slide ranks all 14 rated companies by EV/Revenue (CY2027E) against a sector median of 3.5x.

    We rank all 14 rated companies on EV/Revenue for CY2027E, and the sector median sits at 3.5x. The premium tier trades at 25.6x while the discount tier sits at 1.5x — a spread growth estimates alone cannot explain. Practitioners price this industry on revenue rather than EBITDA, and our validated coverage supports following that convention. So what: the median tells you where the sector sits, but the tiers tell you where the argument actually happens.

    Everything on this page

    03 · PUBLIC MARKET VALUATION Pipeline Optionality Separates the Premium End from the Discount End EV / Revenue (CY2027E) · all 14 rated companies, sorted descending · sector median 3.5x · EV/Revenue is the lens because practitioners price this growth set on revenue · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (14 of 26 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (14 of 26 companies), so this report follows it. Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / Revenue (CY2027E) basis. Panel commentary is a NeuraCap view. Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 25.6x CORE · median 3.5x DISCOUNT · median 1.5x Sector median 3.5x WHAT SEPARATES THE TWO ENDS The top sells optionality. Four companies at the premium end carry a 25.6x CY2027E revenue multiple. Their forward valuations already credit forecast revenue, placing greater weight on durable clinical evidence and follow-on indications. The lower end needs proof. Four companies at the discount end carry a 1.5x CY2027E revenue multiple. The group spans clinical-stage and specialty models, so the operating proof point differs by company. Forecasts are already credited. A forward multiple incorporates anticipated revenue. A premium that remains therefore sits alongside expectations for durability, label expansion or additional pipeline value.

  9. 09
    03 · VALUATION DRIVERS

    Profitability Separates the Two Ends: Names Above the 31% Margin Line Carry 3.2x Against 1.9x Below It

    This slide splits median EV/Revenue by revenue-growth cohort and by EBITDA-margin cohort, each split at its covered median.

    We test two potential drivers of valuation: revenue growth and EBITDA margin. Growth alone barely moves the multiple — 3.0x above the growth bar versus 3.4x below it — but margin tells a sharper story: names above the 31% margin line carry 3.2x against 1.9x below it. This is an association we observe in the data, not a claim that margin causes the multiple. So what: profitability, more than growth, is where the valuation conversation should start.

    Everything on this page

    03 · VALUATION DRIVERS Profitability Separates the Two Ends: Names Above the 31% Margin Line Carry 3.2x Against 1.9x Below It Median EV / Revenue (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=5; slower n=5; higher-margin n=4; lower-margin n=3). Driver readings are NeuraCap views on the supplied data — association, not causation. Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/Revenue, median per cohort · growth split at 14% · EBITDA-margin split at 31% Above the Growth Bar: The Lower Valuation Among five companies above the growth bar, the valuation sits at 3.0x. High forecast growth still needs support from payer access, prescriber depth or de-risked pipeline evidence. Below the Growth Bar: The Higher Valuation Among five companies below the growth bar, the valuation sits at 3.4x. The narrow contrast indicates that forecast growth alone does not sort the sample cleanly. Durability Remains the Commercial Test For launched assets, persistence, gross-to-net performance and label breadth shape revenue quality. For clinical assets, pivotal evidence and probability of technical and regulatory success remain central.

  10. 10
    03 · SITUATION MAP

    Value Today Sits with Marketed Products, and the Next Proof Point Sits in the Clinic

    This slide maps rated companies on EV/Revenue versus the sector median against revenue growth versus the covered median.

    We plot each company on two axes — valuation against the 3.5x sector median, and growth against the 14% covered median — to see where value sits today versus where the next proof point is expected. Value concentrates with marketed products already generating durable revenue, while the next re-rating catalyst sits with names still in the clinic. These are observations on the data, not recommendations. So what: this map tells you which companies are being priced for what they've proven, and which for what they might prove next.

    Everything on this page

    03 · SITUATION MAP Value Today Sits with Marketed Products, and the Next Proof Point Sits in the Clinic Cut on EV / Revenue vs the sector median (3.5x) (rows) and revenue growth vs the covered median (14%) (columns) · 4 rated names without the second measure are not mapped · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Premium with Growth Above-median multiple · above-median revenue growth 2 names Axsome Therapeutics, Inc. (AXSM) · Stoke Therapeutics, Inc. (STOK) These companies combine above-benchmark valuation with above-benchmark forecast growth. The priority is to sustain expectations through execution, payer access and the next clinical or commercial milestone. Premium Before Growth Above-median multiple · below-median revenue growth 2 names Jazz Pharmaceuticals plc (JAZZ) · Biohaven Ltd. (BHVN) These companies carry above-benchmark valuation despite below-benchmark forecast growth. Defending that position requires durable revenue quality, credible pipeline optionality or a clear path to renewed growth. Growth Awaiting Repricing Below-median multiple · above-median revenue growth 3 names Neurocrine Biosciences, Inc. (NBIX) · Supernus Pharmaceuticals, Inc. (SUPN) · Alpha Cognition Inc (ACOG) These companies show above-benchmark forecast growth while trading below the valuation benchmark. Closing the gap depends on proving revenue durability, retention and the economics of commercial expansion. Proof Still Required Below-median multiple · below-median revenue growth 3 names Biogen Inc. (BIIB) · ACADIA Pharmaceuticals Inc. (ACAD) · Collegium Pharmaceutical, Inc. (COLL) These companies sit below both benchmarks. Management has to identify the most credible operating milestone before adding cost or broadening investment.

  11. 11
    03 · THE AGENDA

    The Milestone a Company Takes on Next Sits at the Centre of the Value Debate

    This slide frames the questions an owner or acquirer should resolve based on the milestone each company is approaching.

    We translate the situation map into questions: what's the next milestone, and does the market already expect it? For clinical-stage names, that's the pivotal readout; for commercial names, it's payer access and persistence. So what: knowing which milestone the market is pricing in tells you where to focus attention before the next re-rating.

    Everything on this page

    03 · THE AGENDA The Milestone a Company Takes on Next Sits at the Centre of the Value Debate NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 Fund the Next De-Risking Event Prioritise the pivotal readout, regulatory interaction or patient-enrichment work that can materially change probability of technical and regulatory success. What changes the answer: The answer changes when timing, enrolment or endpoint risk makes the next readout less decisive. Deepen Commercial Productivity Concentrate investment on payer access, specialist prescriber depth and persistence before expanding reach. Reusable infrastructure matters most when another indication or product can fill it. What changes the answer: The answer changes when access is broad and incremental demand supports wider coverage. Build Portfolio Breadth Selectively Use label expansion, licensing or build-versus-buy choices to reduce reliance on a single asset without diluting capital across low-conviction programs. What changes the answer: The answer changes when a follow-on program offers clear strategic fit and a credible path to differentiated evidence. Protect Revenue Durability Address loss-of-exclusivity exposure, gross-to-net erosion and prior-authorisation friction through product mix, lifecycle planning and disciplined cost structure. What changes the answer: The answer changes when the revenue base has sufficient duration to support reinvestment in growth.

  12. 12
    SECTION 04

    04

    This divider introduces section four, covering precedent transactions in the sector.

    We move to the deal record. Buyers have paid for both marketed CNS brands and strategic clinical assets — the pattern behind those transactions is what we unpack next.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Buyers Agreed to Pay for Marketed Brands and Strategic CNS Assets Large pharmaceutical and specialty buyers have pursued assets that extend or reinforce neuroscience franchises. 04 of 06 Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12

  13. 13
    04 · DEAL CASE STUDIES

    Franchise Fit Runs Through the Transaction Record, Across Marketed and Clinical Assets

    This slide presents three of eleven disclosed-terms transactions as case studies illustrating franchise fit.

    We highlight three of the eleven disclosed-terms transactions in this record, spanning marketed and clinical assets. The selected deals range from $795M to $13.8B, and in each case the buyer's rationale runs through franchise fit rather than deal size alone. These multiples are LTM at announcement and are not directly comparable to the CY2027E public basis. So what: strategic fit, not stage of development, is the common thread across the sector's largest transactions.

    Everything on this page

    04 · DEAL CASE STUDIES Franchise Fit Runs Through the Transaction Record, Across Marketed and Clinical Assets 3 of 11 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 32 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate precedent id; no evidence record); figures are shown as recorded in the filing. 21 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13 Aug-2026 $2.8B Indivior Pharmaceuticals Inc. Indivior Pharmaceuticals Inc. completed the acquisition of Supernus Pharmaceuticals, Inc. EV / LTM revenue 3.4x EV / LTM EBITDA 18.6x WHY THE DEAL HAPPENED The transaction suggests value in combining marketed portfolios and specialist commercial capabilities. The fit may support broader use of established prescriber relationships and operating infrastructure. HOW THE TARGET WAS VALUED Supernus Pharmaceuticals, Inc. (SUPN) was valued at $2.8B, equal to 3.4x revenue and 18.6x EBITDA. The revenue multiple provides the cleaner comparison with the public-company lens. Jun-2025 $795M Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals, Inc. (SUPN) agreed to acquire Sage Therapeutics, Inc., extending its CNS… EV / LTM revenue 3.4x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The transaction suggests a specialty buyer using an existing commercial platform to add CNS assets. It also points to the strategic value of portfolio expansion within a focused prescriber base. HOW THE TARGET WAS VALUED Sage Therapeutics, Inc. was valued at $795M and 3.4x revenue. That multiple benchmarks the transaction against commercial-stage revenue rather than near-term profit. Dec-2023 $13.8B Bristol Myers Squibb Company Bristol Myers Squibb Company agreed to acquire Karuna Therapeutics, Inc. in a large neuroscience… EV / LTM revenue n/a EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The transaction suggests large-pharma appetite for a later-stage CNS asset that can add a new growth platform. The buyer’s scale also offers commercial and development capacity around the target’s programs. HOW THE TARGET WAS VALUED Karuna Therapeutics, Inc. was valued at $13.8B. The disclosed value benchmarks the scale of strategic commitment to a later-stage neuroscience asset.

  14. 14
    SECTION 05

    05

    This divider introduces section five, covering strategic implications for capital allocation.

    We close the analysis with strategic implications. Capital allocation should follow the next value-defining readout, commercial milestone or franchise opportunity — that's the discipline we lay out next.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS Strengthen the Evidence Behind Growth Before Expanding the Cost Base Capital allocation should follow the next value-defining readout, commercial milestone or franchise opportunity. 05 of 06 Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14

  15. 15
    05 · STRATEGIC IMPLICATIONS

    Buyers Pay up Where Clinical Proof Is Paired with Durable Commercial Performance

    This slide sets out the questions this data raises for owners, management teams and boards over the next twelve months.

    We find that buyers pay up where clinical proof is paired with durable commercial performance — neither alone commands the premium. For owners, that means choosing the proof point that matters; for management teams, matching cost to revenue quality; for boards, testing build versus buy. So what: the next twelve months should be spent closing the gap between where a company sits today and where the data says value concentrates.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS Buyers Pay up Where Clinical Proof Is Paired with Durable Commercial Performance NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15 FOR OWNERS Choose the Proof Point That Matters Align capital allocation with the milestone most likely to change how the business is assessed: pivotal evidence, payer access, persistence, label expansion or portfolio breadth. FOR MANAGEMENT TEAMS Match Cost to Revenue Quality Scale commercial and development spending only where the expected revenue has durable access, identifiable prescribers and sufficient exclusivity. FOR BOARDS Test Build Versus Buy Compare internal development with licensing or acquisition where a new asset can use existing clinical, regulatory or commercial infrastructure.

  16. 16
    SECTION 06

    06

    This divider introduces the appendix, covering the full comparable universe, methodology and sources.

    We close with the full universe behind every figure in this report — the comparables, the methodology and the source index. Everything you've seen traces back to a filing or a consensus estimate you can open yourself.

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16

  17. 17
    06 · PUBLIC COMPARABLES (1 OF 1)

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier

    This appendix lists all 14 rated companies on EV/Revenue (CY2027E), grouped by valuation tier, with 12 companies unrated.

    We list all 14 rated companies here, grouped by tier against the 3.5x sector median, alongside the 12 names that carry no eligible EV/Revenue multiple. Every ticker links to its underlying source so you can trace any figure back to its filing. So what: this is the full evidentiary base behind every multiple quoted earlier in the deck.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (3.5x); amber marks below · 14 rated companies; 12 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 14 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥10.6x · median 25.6x · 4 companies Biohaven Ltd. BHVN Clinical-stage CNS biotech $1.9B 42.4x -43% n/a n/a Stoke Therapeutics, Inc. STOK Clinical-stage CNS biotech $1.2B 27.8x 40% n/a n/a GH Research PLC GHRS Clinical-stage CNS biotech $1.2B 23.4x n/a n/a n/a Bright Minds Biosciences Inc. DRUG Clinical-stage CNS biotech $273M 12.1x n/a n/a n/a CORE — 2.1x–10.6x · median 3.5x · 6 companies Axsome Therapeutics, Inc. AXSM Clinical-stage CNS biotech $9.9B 6.3x 62% 7% 69 Relmada Therapeutics, Inc. RLMD Clinical-stage CNS biotech $164M 5.0x n/a n/a n/a Jazz Pharmaceuticals plc JAZZ Clinical-stage CNS biotech $18.5B 3.7x 6% 43% 49 Biogen Inc. BIIB Diversified neuroscience franchises $36.0B 3.4x 2% 34% 37 Neurocrine Biosciences, Inc. NBIX Clinical-stage CNS biotech $13.3B 3.0x 15% 31% 47 Alpha Cognition Inc ACOG Clinical-stage CNS biotech $133M 2.7x 92% n/a n/a DISCOUNT — <2.1x · median 1.5x · 4 companies ACADIA Pharmaceuticals Inc. ACAD Clinical-stage CNS biotech $2.7B 1.9x 13% 16% 28 Supernus Pharmaceuticals, Inc. SUPN Specialty and branded-generic neurology $2.2B 1.6x 56% 20% 76 Collegium Pharmaceutical, Inc. COLL Specialty and branded-generic neurology $1.1B 1.3x 1% 35% 35 Cognition Therapeutics, Inc. CGTX Clinical-stage CNS biotech $34M 0.8x n/a n/a n/a

  18. 18
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This appendix lists all eleven disclosed-terms precedent transactions, newest first, out of thirty-two recorded.

    We list all eleven transactions with disclosed terms here, newest first, out of 32 transactions recorded in total. Deal values link to the underlying filing, and multiples are LTM at announcement rather than the CY2027E basis used elsewhere in this report. So what: this is the complete, traceable transaction record behind the case studies shown earlier.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 11 transactions with disclosed terms in this tier (32 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 32 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate precedent id; no evidence record); figures are shown as recorded in the filing. 21 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Aug-2026 Indivior Pharmaceuticals Inc. → Supernus Pharmaceuticals, Inc. $2.8B 3.4x 18.6x Indivior Pharmaceuticals Inc. completed its acquisition of Supernus Pharmaceuticals, Inc. (SUPN), combining businesses with established CNS commercial exposure. Jun-2025 Supernus Pharmaceuticals, Inc. → Sage Therapeutics, Inc. $795M 3.4x n/a Supernus Pharmaceuticals, Inc. (SUPN) announced its acquisition of Sage Therapeutics, Inc., pointing to the value of adding CNS assets to an existing specialty platform. May-2025 Sanofi → Vigil Neuroscience, Inc. $431M n/a n/a Sanofi announced its acquisition of Vigil Neuroscience, Inc., indicating continued strategic interest in clinical neuroscience assets. Jan-2025 Johnson & Johnson → Intra-Cellular Therapies, Inc. n/a 5.4x n/a Johnson & Johnson announced its acquisition of Intra-Cellular Therapies, Inc., adding a commercial-stage CNS business to a broader pharmaceutical portfolio. Dec-2023 Bristol Myers Squibb Company → Karuna Therapeutics, Inc. $13.8B n/a n/a Bristol Myers Squibb Company announced its acquisition of Karuna Therapeutics, Inc., highlighting large-pharma appetite for later-stage neuroscience programs. Dec-2023 AbbVie Inc. → Cerevel Therapeutics Holdings, Inc. $8.9B n/a n/a AbbVie Inc. announced its acquisition of Cerevel Therapeutics Holdings, Inc., adding a portfolio of neuroscience programs across development stages. Oct-2021 Supernus Pharmaceuticals, Inc. → Adamas Pharmaceuticals, Inc. n/a 3.3x n/a Supernus Pharmaceuticals, Inc. (SUPN) announced its acquisition of Adamas Pharmaceuticals, Inc., extending its presence in marketed neurology products. Oct-2021 Pacira Biosciences, Inc. → Supernus Pharmaceuticals, Inc. n/a 0.7x n/a Pacira Biosciences, Inc. completed its acquisition of Supernus Pharmaceuticals, Inc. (SUPN), linking established specialty pharmaceutical operations. Apr-2020 Supernus → U.S. Worldmeds CNS Portfolio n/a 2.0x n/a Supernus announced its acquisition of the U.S. Worldmeds CNS Portfolio, consistent with adding marketed products to an existing commercial infrastructure.

  19. 19
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This appendix continues the list of disclosed-terms precedent transactions, newest first.

    We continue the transaction list here, completing the eleven disclosed-terms deals out of 32 recorded. As before, every deal value links to its filing and multiples are LTM at announcement, not the CY2027E basis. So what: together with the prior page, this gives you the full disclosed-terms record to check against your own screen.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 11 transactions with disclosed terms in this tier (32 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 32 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate precedent id; no evidence record); figures are shown as recorded in the filing. 21 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Nov-2018 InvaGen Pharmaceuticals Inc. → Avenue Therapeutics, Inc. $641M n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Jan-2017 Piramal Critical Care → Mallinckrodt (Intrathecal Spasticity and Pain Drugs) n/a 4.6x n/a

  20. 20
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    This slide explains the sources, assumptions and data-quality treatment behind the report.

    We show how this report was built: what was included, what was excluded, and where every underlying disclosure lives. Every figure links to the record it was taken from, and where it doesn't, the appendix names the source and the basis for reading it. So what: you can verify any number in this deck without taking our word for it.

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice 20 VALUATION BASIS Primary valuation basis: EV / Revenue on CY2027E consensus (14 of 26 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (14 of 26 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Neurology and CNS Therapeutics and it clears the coverage gate with 14 of 26 companies (54%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (7 of 26 names with a meaningful EBITDA). DATA QUALITY & EXCLUSIONS 118 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 679 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (678) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  21. 21

    Value Sits with Credible Clinical Proof, Durable Revenue and Clear Franchise Fit.

    This closing slide restates the report's conclusion that value sits with clinical proof, durable revenue and franchise fit.

    We close where we started: value in this sector sits with credible clinical proof, durable revenue and clear franchise fit. The companion tables beside this deck carry the full universe and source index for any figure you want to trace further.

    Everything on this page

    Value Sits with Credible Clinical Proof, Durable Revenue and Clear Franchise Fit. NeuraCap AI — Neurology and CNS Therapeutics Coverage September 2026 · Prepared by NeuraCap AI · Confidential Neurology and CNS Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 21

Sources and methodology

This report covers Neurology and CNS Therapeutics (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Neurology and CNS Therapeutics) with market data and consensus estimates as of September 28, 2026. The company universe is the 26 listed companies whose core business is Neurology and CNS Therapeutics according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: ACADIA Pharmaceuticals Inc. (ACAD), Alpha Cognition Inc (ACOG), Amylyx Pharmaceuticals, Inc. (AMLX), Alto Neuroscience, Inc. (ANRO), Anavex Life Sciences Corp. (AVXL), Axsome Therapeutics, Inc. (AXSM), Biohaven Ltd. (BHVN), Biogen Inc. (BIIB), Cognition Therapeutics, Inc. (CGTX), COMPASS Pathways plc (CMPS), Collegium Pharmaceutical, Inc. (COLL), Bright Minds Biosciences Inc. (DRUG), Eledon Pharmaceuticals, Inc. (ELDN), GH Research PLC (GHRS), Jazz Pharmaceuticals plc (JAZZ), MediciNova, Inc. (MNOV), Neurocrine Biosciences, Inc. (NBIX), Neumora Therapeutics, Inc. Common Stock (NMRA), Ovid Therapeutics Inc. (OVID), Praxis Precision Medicines, Inc. (PRAX), Rapport Therapeutics, Inc. Common Stock (RAPP), Relmada Therapeutics, Inc. (RLMD), Stoke Therapeutics, Inc. (STOK), Supernus Pharmaceuticals, Inc. (SUPN), Tonix Pharmaceuticals Holding Corp. (TNXP), Xenon Pharmaceuticals Inc. (XENE). The market map groups them by business vertical — Clinical-stage CNS biotech: 23 companies (JAZZ, NBIX, AXSM, PRAX, AMLX, ACAD, XENE, BHVN, STOK, GHRS, RAPP, CMPS, ANRO, DRUG, OVID, RLMD, ELDN, ACOG, NMRA, AVXL, MNOV, CGTX, TNXP); Specialty and branded-generic neurology: 2 companies (SUPN, COLL); Diversified neuroscience franchises: 1 company (BIIB). 14 of the 26 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

Scope and company universe

This report covers Neurology and CNS Therapeutics (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Neurology and CNS Therapeutics) with market data and consensus estimates as of September 28, 2026. The company universe is the 26 listed companies whose core business is Neurology and CNS Therapeutics according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: ACADIA Pharmaceuticals Inc. (ACAD), Alpha Cognition Inc (ACOG), Amylyx Pharmaceuticals, Inc. (AMLX), Alto Neuroscience, Inc. (ANRO), Anavex Life Sciences Corp. (AVXL), Axsome Therapeutics, Inc. (AXSM), Biohaven Ltd. (BHVN), Biogen Inc. (BIIB), Cognition Therapeutics, Inc. (CGTX), COMPASS Pathways plc (CMPS), Collegium Pharmaceutical, Inc. (COLL), Bright Minds Biosciences Inc. (DRUG), Eledon Pharmaceuticals, Inc. (ELDN), GH Research PLC (GHRS), Jazz Pharmaceuticals plc (JAZZ), MediciNova, Inc. (MNOV), Neurocrine Biosciences, Inc. (NBIX), Neumora Therapeutics, Inc. Common Stock (NMRA), Ovid Therapeutics Inc. (OVID), Praxis Precision Medicines, Inc. (PRAX), Rapport Therapeutics, Inc. Common Stock (RAPP), Relmada Therapeutics, Inc. (RLMD), Stoke Therapeutics, Inc. (STOK), Supernus Pharmaceuticals, Inc. (SUPN), Tonix Pharmaceuticals Holding Corp. (TNXP), Xenon Pharmaceuticals Inc. (XENE). The market map groups them by business vertical — Clinical-stage CNS biotech: 23 companies (JAZZ, NBIX, AXSM, PRAX, AMLX, ACAD, XENE, BHVN, STOK, GHRS, RAPP, CMPS, ANRO, DRUG, OVID, RLMD, ELDN, ACOG, NMRA, AVXL, MNOV, CGTX, TNXP); Specialty and branded-generic neurology: 2 companies (SUPN, COLL); Diversified neuroscience franchises: 1 company (BIIB). 14 of the 26 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

118 records failed a validation gate and never feed a statistic in this report (103 excluded from aggregate; 15 quarantined). Each exclusion, with its reason: ACOG — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ACOG — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ACOG — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ACOG — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AMLX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AMLX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AMLX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AMLX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ANRO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ANRO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ANRO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ANRO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AVXL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AVXL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AVXL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AXSM — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · AXSM — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · AXSM — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AXSM — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AXSM — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BHVN — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BHVN — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BHVN — Implied EBITDA margin -350.5% outside the plausible band [-100%, 80%] (effect: quarantined) · BHVN — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BHVN — Implied EBITDA margin -835.1% outside the plausible band [-100%, 80%] (effect: quarantined) · further items are listed in the companion tables.

Primary valuation basis and how it was chosen

Primary valuation basis: EV / Revenue on CY2027E consensus (14 of 26 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (14 of 26 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Neurology and CNS Therapeutics and it clears the coverage gate with 14 of 26 companies (54%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (7 of 26 names with a meaningful EBITDA). The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 7 of 26 companies; EV / rEVenue: 21 of 26 companies; P/E: 8 of 26 companies. 17 companies show a non-meaningful P / E denominator and are excluded from that statistic.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥10.6x, Core 2.1x–10.6x, Discount <2.1x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 3.5x = median(ev_revenue CY2027E) (14 rated companies) · 25.6x = median(ev_revenue CY2027E) within Premium tier (n=4) · 3.5x = median(ev_revenue CY2027E) within Core tier (n=6) · 1.5x = median(ev_revenue CY2027E) within Discount tier (n=4) · 3.0x = median(ev_revenue CY2027E) | growth ≥ 14% (n=5) · 3.4x = median(ev_revenue CY2027E) | growth < 14% (n=5) · 3.2x = median(ev_revenue CY2027E) | EBITDA margin ≥ 31% (n=4) · 1.9x = median(ev_revenue CY2027E) | EBITDA margin < 31% (n=3) · 47% = median Rule of 40 score (revenue growth + EBITDA margin) (n=7)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Neurology and CNS Therapeutics recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 32 transactions were recorded for this industry; 11 are shown. 21 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 19 × deal value unit unresolved; 12 × no evidence record; 1 × duplicate precedent id. Case studies lead with the 3 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 683 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

Sources linked in the report

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Neurology and CNS Therapeutics?

Company valuation reports run the same method against a single business — public or private.